KRAS and colorectal cancer: More importantly, the failure of improvement may be due to a differential effect on the response rate from the addition of cetuximab according to the molecular status of the tumour, as seen with K-ras mutation and cetuximab plus FOLFOX in colorectal cancer (Bokemeyer et al, 2008).